Founded in 2003, Physiogenex has built its expertise in metabolic diseases (obesity, type 2 diabetes, NASH/fibrosis, diabetic nephropathy, inflammation, dyslipidemia and cardiovascular diseases) over the years with a strong and dedicated team.
Pioneers in the development of predictive animal nutritional models, our aim is to help pharmaceutical, biotechnology and nutraceutical companies to optimize preclinical drug candidates’ studies and reduce the cost and time to market of new therapies. Based on its scientific skills and R&D program, Physiogenex is continuously developing new innovative animal models for metabolic disorders to offer optimized and innovative customized solutions to our clients. All our knowledge and scientific expertise are applied to provide our customers reliable and quality results.
Offices in France: